In 2016, The Worldwide Market For Biotech API Manufacturing Services Will Reach $4.36bn Predicts A New Visiongain Report

03 September 2016
Pharma

A new report by visiongain predicts that the worldwide market for biotech API manufacturing services will reach $4.36bn in 2016. This forecast and others appears in Biological Drug API Manufacturing Services World Industry and Market Predictions 2016-2026: Mammalian Cell Culture, Microbial Fermentation, Human Growth Hormones, Insulin, Interferons, Monoclonal Antibodies, Vaccine published in August 2016. Visiongain is a business information provider based in London, UK.

Biological Drug API Manufacturing Services World Industry and Market Predictions 2016-2026: Mammalian Cell Culture, Microbial Fermentation, Human Growth Hormones, Insulin, Interferons, Monoclonal Antibodies, Vaccine reviews the contract active pharmaceutical ingredient (API) manufacturing market for biologics. This study gives quantitative and qualitative analysis for that overall world market, as well as for countries and other submarkets, including the mammalian cell culture and microbial fermentation segments. This report assesses leading applications and significant developments within each, as well as drivers and restraints for them. Future trends that will affect the biotech API manufacturing services market are also examined. In addition, this study profiles leading contract manufacturing organisations (CMOs) in the outsourcing market and assesses their outlooks. Visiongain provides forecasts revenues for the period 2015 to 2026 for the biotech API manufacturing services market, as well as for therapeutic applications.

“The outsourcing of biotech API contract manufacturing to contract manufacturing organizations around the world offers a number of benefits. As pharmaceutical companies around the world aim to cut costs in an increasingly crowded market CMOs offer scheduled and affordable services; without the high cost associated with building new manufacturing facilities. Contract manufacturing organizations also benefit smaller pharmaceutical companies, who outsource to access expertise and gain entry to markets they otherwise would not be able to reach; particular in emerging nations where the industry is on a rapid rise. Ultimately biotech API contract manufacturing helps to increase the interconnected nature of the pharmaceutical industry benefiting a number of groups as in continues to grow in the ever expanding pharmaceutical industry. “

- Arvind Deol, pharmaceutical market analyst, visiongain, 2016

The report will focus on the five main segments of the market:

• Monoclonal antibody (mAb) therapies
• Vaccines
• Insulin therapies
• Interferon therapies
• Growth hormones.

This independent, 238-page report guarantees you will remain better informed than your competition. With 135 tables and figures examining the Biological API Manufacturing market space, the report gives you a visual, one-stop breakdown of your market.

Our work also shows individual revenue forecasts to 2026 for these national markets:

• The EU, including the five leading markets (UK, Germany, France, Italy and Spain).
• The US
• Japan
• Switzerland
• Emerging markets such as the BRIC (Brazil, Russia, India, and China) countries, South Korea and Singapore

Recent News

“Pharmaceutical Contract Manufacturing market set to grow to $138bn by 2024” says new Visiongain report

The technologies that will be in the greatest demand in this decade are those that provide flexibility and faster turnover times for pharma companies.

19 August 2019

Read

“Global Ophthalmic Drugs market set to grow to $32bn by 2024” says Visiongain report

Successful harnessing of the opportunities for growth in the ophthalmic pharmaceuticals market will depend upon the development of novel products with technologies that increase clinical effectiveness and development of products for previously-untreated ophthalmic conditions.

15 August 2019

Read

“Global Medical Device Contract Manufacturing market set to grow to $130bn by 2024” says new Visiongain report

The available reduced costs of outsourced manufacturing combined with access to the innovation power of CMOs are major drivers behind the decision to outsource manufacturing processes.

06 August 2019

Read

“3D Printing for Healthcare market is worth $872 million in 2019” says Visiongain report

The main appeal of 3D printed healthcare products to professionals is that each unit can be personalised to fit the recipient.

02 August 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever